[
  {
    "ts": null,
    "headline": "The AI Rally Is on Pause. Try These 11 Non-Tech Stocks.",
    "summary": "Highflying artificial intelligence stocks look increasingly risky, so investors should allocate some money to names that aren’t likely to plunge if the AI trade falters.",
    "url": "https://finnhub.io/api/news?id=bc6ba4a4a2690d3f81a83a96554a9fb3c76f01c5e59d08f8d0306e0a4670eb5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759173300,
      "headline": "The AI Rally Is on Pause. Try These 11 Non-Tech Stocks.",
      "id": 136933913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Highflying artificial intelligence stocks look increasingly risky, so investors should allocate some money to names that aren’t likely to plunge if the AI trade falters.",
      "url": "https://finnhub.io/api/news?id=bc6ba4a4a2690d3f81a83a96554a9fb3c76f01c5e59d08f8d0306e0a4670eb5c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): A Dividend Aristocrat With Unmatched Stability",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 10 Best Recession Proof Dividend Stocks to Buy. Johnson & Johnson (NYSE:JNJ), founded in 1886 to produce sterile surgical supplies after the Civil War, has since grown into one of the largest global pharmaceutical and medical device companies. Unlike some drugmakers that rely heavily on a single […]",
    "url": "https://finnhub.io/api/news?id=42ece177cf3c940418835af6d28ea99d2d39a405db19245788c5431b0951a0e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759167472,
      "headline": "Johnson & Johnson (JNJ): A Dividend Aristocrat With Unmatched Stability",
      "id": 136934062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 10 Best Recession Proof Dividend Stocks to Buy. Johnson & Johnson (NYSE:JNJ), founded in 1886 to produce sterile surgical supplies after the Civil War, has since grown into one of the largest global pharmaceutical and medical device companies. Unlike some drugmakers that rely heavily on a single […]",
      "url": "https://finnhub.io/api/news?id=42ece177cf3c940418835af6d28ea99d2d39a405db19245788c5431b0951a0e5"
    }
  },
  {
    "ts": null,
    "headline": "Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus",
    "summary": "Genmab, on Monday, announced its plan to buy Merus for about $8 billion. The news sent Merus stock into the stratosphere.",
    "url": "https://finnhub.io/api/news?id=37e94fcfcd6ed7ad62fcbf6fa4bc19ace9a24ea392edc84846627c705d08b09f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759157768,
      "headline": "Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus",
      "id": 136915695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Genmab, on Monday, announced its plan to buy Merus for about $8 billion. The news sent Merus stock into the stratosphere.",
      "url": "https://finnhub.io/api/news?id=37e94fcfcd6ed7ad62fcbf6fa4bc19ace9a24ea392edc84846627c705d08b09f"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of children six years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis (PsO), who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis (PsA). This milestone makes TREMFYA® the first and only IL-23 inhibitor approved for these pediatric indications and builds on the initial FDA approvals in",
    "url": "https://finnhub.io/api/news?id=ec93798764c29c6ee7f313a261658818d643a15eb2fab55d8a40c9c17fddd448",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759147200,
      "headline": "U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor",
      "id": 136915696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of children six years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis (PsO), who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis (PsA). This milestone makes TREMFYA® the first and only IL-23 inhibitor approved for these pediatric indications and builds on the initial FDA approvals in",
      "url": "https://finnhub.io/api/news?id=ec93798764c29c6ee7f313a261658818d643a15eb2fab55d8a40c9c17fddd448"
    }
  }
]